緑内障(Glaucoma)：世界の治験レビュー（2015年上半期版）...市場調査レポートについてご紹介

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Glaucoma 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Five Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Glaucoma to Ophthalmology Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Glaucoma to Ophthalmology Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Unaccomplished Trials of Glaucoma 25
Subjects Recruited Over a Period of Time 30
Clinical Trials by Sponsor Type 31
Prominent Sponsors 32
Top Companies Participating in Glaucoma Therapeutics Clinical Trials 33
Prominent Drugs 34
Latest Clinical Trials News on Glaucoma 35
May 11, 2015: Isarna Presents Positive Preclinical Results Supporting Development of ISTH0036 for the Treatment of Glaucoma 35
May 11, 2015: Promising preclinical data on NCX 667 for glaucoma presented at ARVO by Nicox 35
May 11, 2015: Promising preclinical data on NCX 470 for glaucoma presented at ARVO by Nicox 36
Apr 28, 2015: Avalanche Biotechnologies to Present at Upcoming Scientific Meetings 36
Apr 16, 2015: Isarna Initiates First-in-Human Phase I Trial for ISTH0036 to Treat Advanced Glaucoma 37
Mar 24, 2015: Aerie Pharmaceuticals Completes Enrollment in Second Phase 3 Registration Trial of Rhopressa, Novel Triple-Action Product to Lower Intraocular Pressure in Patients with Glaucoma 37
Clinical Trial Profiles 39
Clinical Trial Overview of Top Companies 39
Novartis AG 39
Clinical Trial Overview of Novartis AG 39
Actavis plc 47
Clinical Trial Overview of Actavis plc 47
Pfizer Inc. 53
Clinical Trial Overview of Pfizer Inc. 53
Santen Pharmaceutical Co., Ltd. 57
Clinical Trial Overview of Santen Pharmaceutical Co., Ltd. 57
Aerie Pharmaceuticals, Inc. 60
Clinical Trial Overview of Aerie Pharmaceuticals, Inc. 60
Merck & Co., Inc. 62
Clinical Trial Overview of Merck & Co., Inc. 62
Valeant Pharmaceuticals International, Inc. 64
Clinical Trial Overview of Valeant Pharmaceuticals International, Inc. 64
QLT Inc. 66
Clinical Trial Overview of QLT Inc. 66
Kowa Company, Ltd. 67
Clinical Trial Overview of Kowa Company, Ltd. 67
Mati Therapeutics Inc. 68
Clinical Trial Overview of Mati Therapeutics Inc. 68
Clinical Trial Overview of Top Institutes / Government 69
Aristotle University Of Thessaloniki 69
Clinical Trial Overview of Aristotle University Of Thessaloniki 69
Medical University of Vienna 70
Clinical Trial Overview of Medical University of Vienna 70
Beijing Tongren Hospital 71
Clinical Trial Overview of Beijing Tongren Hospital 71
Shahid Beheshti University of Medical Sciences 72
Clinical Trial Overview of Shahid Beheshti University of Medical Sciences 72
Moorfields Eye Hospital NHS Foundation Trust 73
Clinical Trial Overview of Moorfields Eye Hospital NHS Foundation Trust 73
Federal University of Sao Paulo 74
Clinical Trial Overview of Federal University of Sao Paulo 74
Kumamoto University 75
Clinical Trial Overview of Kumamoto University 75
University of Colorado Denver 76
Clinical Trial Overview of University of Colorado Denver 76
Wills Eye Institute 77
Clinical Trial Overview of Wills Eye Institute 77
Chinese University of Hong Kong 78
Clinical Trial Overview of Chinese University of Hong Kong 78
Five Key Clinical Profiles 79
Appendix 103
Abbreviations 103
Definitions 103
Research Methodology 104
Secondary Research 104
About GlobalData 105
Contact Us 105
Disclaimer 105
Source 105